Vanda Pharmaceuticals Reports $216.1M Revenue for Fiscal Year 2025, Net Loss of $220.5M

Vanda Pharmaceuticals Inc. reported a total revenue of $216.1 million for the fiscal year ending December 31, 2025, marking a 9% increase from $198.8 million in 2024. The growth was primarily driven by a 24% increase in net product sales of Fanapt®, which reached $117.3 million, up from $94.3 million the previous year. However, sales of HETLIOZ® decreased by 7% to $71.4 million, attributed to increased generic competition and elevated inventory levels at specialty pharmacies. PONVORY® sales remained relatively stable, with a slight decline of 2% to $27.4 million. The company reported a net loss of $220.5 million for 2025, significantly higher than the $18.9 million loss in 2024, largely due to increased research and development expenses and a valuation allowance against deferred tax assets.

In terms of strategic developments, Vanda has made significant strides in its product pipeline. The FDA approved NEREUSTM for the prevention of vomiting induced by motion, and the company is awaiting a decision on the BysantiTM NDA, with a target action date set for February 21, 2026. Additionally, Vanda is pursuing further regulatory approvals for HETLIOZ® for jet lag disorder and insomnia, although recent communications from the FDA indicate challenges in these areas. The company has also initiated a Phase III clinical study for VQW-765, targeting social anxiety disorder, and is actively developing other products, including imsidolimab for generalized pustular psoriasis.

Operationally, Vanda's workforce increased to 533 employees as of December 31, 2025, up from 368 the previous year, reflecting the company's commitment to expanding its commercial and research capabilities. The company has focused on enhancing brand awareness through direct-to-consumer campaigns and strategic marketing initiatives, particularly for Fanapt® and PONVORY®. However, Vanda's reliance on a limited number of specialty pharmacies for distribution poses risks, as any disruptions in these relationships could adversely affect sales.

Looking ahead, Vanda anticipates continued fluctuations in revenue due to various factors, including the impact of generic competition, regulatory developments, and the success of its commercialization efforts. The company has expressed confidence in its ability to sustain operations for at least the next 12 months based on its current cash reserves of $263.8 million, although it may seek additional capital to support ongoing and future projects. The evolving landscape of healthcare reform, particularly regarding pricing and reimbursement policies, remains a critical area of focus that could significantly influence Vanda's financial performance and market position.